ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yupei Zhao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5124850038. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2026: 2 papers

Papers 2

TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated DNA damage repair and IRS2 expression i… Last author DOI 10.1016/j.canlet.2026.218725 ↗
Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102660 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Quan Liao · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Xiaoyan Qiu · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Ming Cui · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Xiaoding Liu · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Shenghua Zhang · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Zhe Cao · 1 shared paper, 2026 · strength 0.24
- Paper TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated… DOI 10.1016/j.canlet.2026.218725 ↗
Yuanyang Wang · 1 shared paper, 2026 · strength 0.24
- Paper TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated… DOI 10.1016/j.canlet.2026.218725 ↗
Jianchun Xiao · 1 shared paper, 2026 · strength 0.24
- Paper TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated… DOI 10.1016/j.canlet.2026.218725 ↗
Yueze Liu · 1 shared paper, 2026 · strength 0.24
- Paper TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated… DOI 10.1016/j.canlet.2026.218725 ↗
Wenhao Luo · 1 shared paper, 2026 · strength 0.24
- Paper TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated… DOI 10.1016/j.canlet.2026.218725 ↗
Yifan Fu · 1 shared paper, 2026 · strength 0.24
- Paper TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated… DOI 10.1016/j.canlet.2026.218725 ↗
Lei You · 1 shared paper, 2026 · strength 0.24
- Paper TRDMT1-mediated mRNA m5C methylation decreases chemotherapy sensitivity by activating homologous recombination-mediated… DOI 10.1016/j.canlet.2026.218725 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.